NEW YORK, Oct. 16, 2022 (GLOBE NEWSWIRE) — Bragar Eagel & Squire, PC, a nationally recognized shareholder rights law firm, is investigating potential claims against EyePoint Pharmaceuticals, Inc. EYPTSpectrum Pharmaceuticals, Inc. SPPIF45 Training Holdings, Inc. FXLVand PROG Holdings, Inc. PRG. Our investigations address whether these companies have violated federal securities laws and/or engaged in other illegal business practices. For more information on each case, see the link provided.

EyePoint Pharmaceuticals, Inc. EYPT

On August 30, 2022, after the market close, EyePoint announced that it had received a subpoena from the United States Attorney for the District of Massachusetts. The subpoena requested documents covering the company’s sales practices for its post-surgical inflammation treatment DEXYCU.

As a result of this news, EyePoint stock fell $0.21 per share, or 2%, to close at $10.00 per share on August 31, 2022.

For more information on the EyePoint exam, visit: https://bespc.com/cases/EYPT

Spectrum Pharmaceuticals, Inc. SPPI

on September 22, 2022, Reuters reported that U.S. Food and Drug Administration advisers “voted against the recommendation of Spectrum Pharmaceuticals’ investigational drug for the treatment of patients with a form of non-small cell lung cancer, which has marginal efficacy, high toxicity, and a lack of dose optimization. The panel’s decision was consistent with.” Information documents released Tuesday by the drug agency that raised concerns about the treatment’s effectiveness compared to existing drugs such as Daiichi Sankyo’s 4568.T Enhertu of AstraZeneca.”

As a result of this news, Spectrum’s stock price fell $0.207 per share, or 32.65%, to close at $0.427 per share on September 23, 2022.

For more information on Spectrum testing, see: https://bespc.com/cases/SPPI

F45 Training Holdings, Inc. FXLV

On or about July 15, 2021 F45 training was conducted…